Your browser doesn't support javascript.
loading
Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors.
Tsuchiya, Nobuhiro; Hosono, Ako; Yoshikawa, Toshiaki; Shoda, Kayoko; Nosaka, Kazuto; Shimomura, Manami; Hara, Junichi; Nitani, Chika; Manabe, Atsushi; Yoshihara, Hiroki; Hosoya, Yosuke; Kaneda, Hide; Kinoshita, Yoshiaki; Kohashi, Kenichi; Yoshimura, Kenichi; Fujinami, Norihiro; Saito, Keigo; Mizuno, Shoichi; Nakatsura, Tetsuya.
Afiliação
  • Tsuchiya N; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
  • Hosono A; Division of Pediatric Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Yoshikawa T; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
  • Shoda K; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
  • Nosaka K; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
  • Shimomura M; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
  • Hara J; Department of Pediatric Hematology and Oncology, Osaka City General Hospital, Miyakojima-hondori, Miyakojima-ku, Osaka, Japan.
  • Nitani C; Department of Pediatric Hematology and Oncology, Osaka City General Hospital, Miyakojima-hondori, Miyakojima-ku, Osaka, Japan.
  • Manabe A; Department of Pediatrics, St Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, Japan.
  • Yoshihara H; Department of Pediatrics, St Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, Japan.
  • Hosoya Y; Department of Pediatrics, St Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, Japan.
  • Kaneda H; Division of Pediatric Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan.
  • Kinoshita Y; Department of Pediatric Surgery, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Japan.
  • Kohashi K; Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Japan.
  • Yoshimura K; Department of Biomedical Statistics, Innovative Clinical Research Center, Kanazawa University, 13-1, Takara-machi, Kanazawa, Ishikawa, Japan.
  • Fujinami N; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
  • Saito K; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
  • Mizuno S; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
  • Nakatsura T; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan.
Oncoimmunology ; 7(1): e1377872, 2017.
Article em En | MEDLINE | ID: mdl-29296538
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Ano de publicação: 2017 Tipo de documento: Article